LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection

Landmark agreement between a leading virtual care company and a pharmaceutical manufacturer establishes an exclusive telehealth co-marketing ...
Business Wire

Antares Pharma Announces Update to QuickShot Testosterone Program

EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ:ATRS) today announced that a meeting was held with the U.S. Food and Drug Administration (FDA) to discuss a registration study for the VIBEX ...
Seeking Alpha

Antares testosterone injector performs well in Phase II trial

Antares' (ATRS) Vibex QuickShot auto injector restored and maintained testosterone levels in a Phase II study of 29 patients. The testosterone-replacement market was worth $2.8B in sales in 2013.
Medscape

FDA Rejects Testosterone Autoinjector Xyosted

The US Food and Drug Administration (FDA) has declined to approve a new drug application (NDA) for testosterone enanthate (Xyosted, Antares Pharma) in a proprietary autoinjector and has raised two ...